ImmVirx
PrivateLast Round
Series B
Jun 5, 2023
Est. Valuation
$49.74M
Total Funding Raised
$48.34M
Company Overview
ImmVirx operates in Healthcare & Life Sciences and is based in New Lambton. Its latest recorded funding round was a Series B round in June 2023.
ImmVirx is a clinical-stage biotechnology company that develops novel oncolytic RNA immunotherapies to treat various types of cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ImmVirx Comparables
Compare ImmVirx with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| IconOVir Bio | 85% | |
| KaliVir Immunotherapeutics | 84% | |
| Virogin Biotech | 81% |
For institutional investors. Book with your work email.
ImmVirx Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jun 5, 2023 | ||||
| Series A | Nov 8, 2021 | ||||
| Series A | May 14, 2021 | ||||
| Seed | Jan 1, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
ImmVirx Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| OneVentures | Series B |
| Acorn Capital | Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 5, 2023
$13M round led by OneVentures.
- Nov 8, 2021
Raised $18.5M led by Acorn Capital
For institutional investors. Book with your work email.
ImmVirx Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about ImmVirx's valuation, stock price, and market status.
Is ImmVirx a public or private company?
ImmVirx is a private company.
What is the current stock price of ImmVirx?
ImmVirx is a private company, so its shares have no public market price. Caplight tracks ImmVirx's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is ImmVirx worth (valuation)?
ImmVirx's valuation is estimated at $49.7M based on funding round data.
Can I buy ImmVirx stock?
ImmVirx shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was ImmVirx's last funding round?
ImmVirx's most recent funding round was Series B on June 5, 2023.
Who are the main investors in ImmVirx?
Key investors in ImmVirx include OneVentures, Acorn Capital.
Will ImmVirx IPO soon?
No public IPO plans have been announced for ImmVirx.
How can I track ImmVirx secondary market activity?
Caplight tracks bids, offers, and trades in ImmVirx's shares on secondary markets.